All Posts

Indexes and overall tone

Wall Street limped into the weekend looking more like a tired marathoner than a sprinter, as major U.S. equity indexes closed a volatile, tariff‑tossed week with modest moves that felt heavier than the point changes implied. The S&P 500 ended the period with its second straight weekly decline, the Dow industrials slipped again under the weight of old‑economy bellwethers, and the Nasdaq managed to dip slightly too over the course of the week that said more about investors’ reluctance to abandon AI and chip darlings than any broad conviction. Small caps, represented by the Russell 2000, fared a little worse as risk appetite waned, leaving the index lower on the week and reminding traders that not all boats rise in a choppy tide.

Macro backdrop and Fed watch

The macro backdrop was busy for a holiday‑shortened stretch, even if the data did more to refine narratives than to rewrite them. Inflation remained the central preoccupation, with attention firmly trained on consumption and the Fed’s preferred gauges as investors weighed whether price pressures are easing enough to justify rate cuts this year or merely drifting toward a higher‑for‑longer plateau. Forecasts for the Personal Consumption Expenditures readings pointed to month‑over‑month gains around 0.2% and year‑over‑year inflation stuck near 2.8%, a level uncomfortably above the Federal Reserve’s 2% objective and therefore conveniently supportive of officials’ cautious rhetoric. Growth indicators remained mixed: a solid GDP backdrop, resilient labor markets, and expansionary but subdued purchasing managers’ indexes all painted the picture of an economy slowing from a sprint to a controlled jog rather than flirting with recession. Consumer sentiment was expected to hold in the mid‑50s on the University of Michigan index, a reading that suggests households are more resigned than exuberant but not yet in the mood for recessionary storytelling.

Rates, yield curve and FOMC expectations

Monetary policy, never far from the market’s mind, loomed large in the background as traders looked ahead to the next’s Jan. 27-28 Federal Open Market Committee (FOMC) gathering, widely expected to result in another “hold‑and‑watch” decision rather than a dramatic pivot. With inflation still running above target and growth not yet cracking, futures markets continued to price in a cautious path of eventual easing, while policymakers signaled that restrictive settings could persist longer than investors would prefer but shorter than the bond market’s more pessimistic scenarios once advertised. The yield curve stayed compressed, with shorter‑dated rates anchored by Fed expectations and longer‑term yields reflecting a blend of inflation uncertainty and term premium, a structure that still whispers late‑cycle rather than early‑recovery.

Tariffs and trade policy

Trade policy took another turn on the geopolitical stage, where tariffs once again auditioned for the role of main antagonist before being asked to stand down—for now. President Trump moved to pause a planned 10% levy on imports from eight NATO allies, offering markets a brief sigh of relief and a reprieve from what had threatened to be another front in the global trade skirmishes. Anxiety around tariffs on European goods faded somewhat as the week progressed, but not enough to restore full risk‑on cheer, particularly with tensions between Washington and European capitals still simmering over strategic assets and influence.

Greenland and geopolitics

The Greenland saga, which might have looked like geopolitical fan fiction a few years ago, continued to cast a peculiar shadow over asset markets. The administration touted a “framework” for a deal around Greenland‑related interests, keeping investors attentive to the intersection of Arctic resources, European relations, and U.S. strategic ambitions. Meanwhile, tensions over U.S.–European control and influence around Greenland and nearby strategic zones remained a recurring theme in foreign‑policy commentary, adding yet another non‑economic variable into models already juggling inflation, growth, and policy risk.

Commodities and bitcoin

In the commodities complex, gold decided subtlety was overrated. The metal surged to fresh record highs, briefly topping the 4,900‑dollar‑per‑ounce mark and logging its best week since 2020 as a weaker dollar, & actually hit $4,989.90 just under the 5k mark as geopolitical jitters, and doubts about the durability of disinflation stoked safe‑haven demand. Silver, not to be outdone, crossed the psychologically loud 100‑dollar threshold closing at $103.36/oz., underscoring just how far the precious‑metals trade has run in a world rediscovering hedges against both inflation and political uncertainty. Oil prices edged 1.56% higher this week to $61.28/bbl as traders weighed President Trump’s remarks about a Greenland‑related “framework” and broader cross‑Atlantic tensions, signaling that crude remains a convenient vessel for pricing geopolitical unease as much as physical supply and demand. Bitcoin trading around $89.5K, for its part, remained a lightning rod for speculation and macro narratives, trading as a high‑beta proxy on liquidity expectations and risk sentiment even as traditional safe havens stole the week’s spotlight.

Eli Lilly and big pharma

On the corporate front, Eli Lilly (LLY, $1,064.29, +3.03% over the last 5-days) continued to behave more like a marquee tech name than a staid pharmaceutical concern. Shares climbed this week, helped by the U.S. Food and Drug Administration granting Breakthrough Therapy designation to sofetabart mipitecan, an oncology candidate for a subset of ovarian cancer patients, reinforcing the company’s reputation as a central player in both obesity and cancer therapeutics. Analysts kept up a drumbeat of bullishness, with estimates and coverage reiterating the view that Lilly’s earnings trajectory and drug pipeline justify its lofty valuation and trillion‑dollar market capitalization, even if shorter‑term volatility occasionally reminds investors that gravity has not been formally repealed.

Chips, AI hardware and foundries

The semiconductor and AI hardware narrative remained dominated by a familiar cast of characters, with Taiwan Semiconductor Manufacturing Company, Nvidia, Apple, Micron, Broadcom, and Intel all central to the week’s conversations. TSMC’s role as the indispensable foundry to Nvidia (NVDA, $187.67, +.33% over the last 5-days), Apple, and other chip leaders was once again underscored, with the company’s ongoing multibillion‑dollar expansion in Arizona seen as both a hedge against geopolitical risk and a vote of confidence in the long‑term AI and high‑performance‑computing boom. Nvidia retained its status as the poster child of AI infrastructure, with fresh analyst commentary highlighting its dominant share of data center accelerators and raising price targets on the premise that trillions of dollars in AI‑related capex are still ahead. Micron (MU, $399.65, +18.72% over the last 5-days), riding the coattails of insatiable AI memory demand, enjoyed continued enthusiasm as rising DRAM prices and long‑term supply contracts reinforced the notion that the memory cycle has turned decisively in its favor. Broadcom, meanwhile, stayed in the frame as a critical enabler of AI networking and custom chips, benefiting from its position at the heart of data center plumbing even as investors debated just how long the current spending cycle can persist.

Intel and earnings disappointments

Intel (INTC, $45.07, -6.73% over the last 5-days) had a more complicated week, with the stock sliding after earnings disappointed investors who had come to expect a cleaner turnaround narrative from the once‑dominant chipmaker. The company’s soft results, coupled with cautious guidance, weighed on the broader Dow and tech complex, reminding markets that not every player in the AI ecosystem is benefiting equally from the current wave of spending. At the same time, some commentary pointed out that Intel’s recent rally had left it vulnerable to even modest underperformance, and the reaction may have reflected expectations as much as fundamentals.

Big Tech, EVs and software names

Big Tech and adjacent names continued to command attention. Apple remained a core holding in many AI‑and‑ecosystem portfolios, with its role as both a device maker and potential beneficiary of on‑device intelligence keeping it central to discussions about the next leg of tech hardware demand. Meta stayed in focus as investors weighed its heavy AI infrastructure spending against the durability of its advertising franchise and the potential upside of new monetization initiatives. Tesla remained a lightning rod, with attention on its progress in autonomous driving and new services—such as expanded robotaxi offerings—helping to sustain speculative interest despite ongoing questions about growth, competition, and margins. Palantir continued to be cast as a high‑growth software name at the intersection of AI and data analytics, with deals and long‑term contracts feeding expectations of continued revenue expansion and a maturing commercial business. Tesla (TSLA, $449.06, +2.39%) as Elon Musk spoke positively at Davos about robot axis and beyond.

Networks, cloud, nuclear and prop‑tech

Beyond the mega‑caps, the broader technology and digital‑economy cohort offered its own color. Nokia (NOK, $6.77., +2.42% over the last 5-days) stayed part of the conversation around network infrastructure and 5G‑and‑beyond deployments, a space that benefits from rising data consumption but has to wrestle with cyclical carrier spending. Oracle featured in discussions about cloud and enterprise software, as investors weighed its position in databases and infrastructure‑as‑a‑service against larger rivals in an increasingly AI‑centric IT spending landscape. Oklo, representative of the new generation of nuclear‑technology developers, continued to draw attention from investors looking for long‑duration plays on clean baseload power, even as regulatory and financing hurdles remained front and center. Opendoor, emblematic of prop‑tech’s attempt to algorithmically tame the housing market, sat at the intersection of real‑estate cycles, interest rates, and investor tolerance for business models that depend on liquidity and price stability in historically volatile assets.

Defensives and cyclicals: McDonald’s and Rio Tinto

Outside of tech and healthcare, stalwarts like McDonald’s (MCD, $309.25, +.20%) and Rio Tinto (RIO, $90.43, +4.73%) reminded markets that cash‑flow reliability still has an audience. McDonald’s remained a defensive favorite, with its global footprint and pricing power offering investors a way to participate in consumer spending without betting heavily on the most economically sensitive categories. Rio Tinto, by contrast, provided exposure to industrial metals I.e. copper that hit new highs, and global growth expectations, its fortunes closely tied to both Chinese demand and broader infrastructure‑and‑energy transitions.

Deals, M&A and IPO mood

In dealmaking, the week delivered at least one headline to remind investors that corporate strategists have not entirely gone into hibernation. Capital One announced an agreement to acquire corporate‑card and spend‑management platform Brex for roughly 5 billion dollars, a price that represents a sharp discount to the start‑up’s peak private‑market valuation and a telling snapshot of how the late‑cycle funding boom has deflated. The transaction highlighted how established financial institutions are still using acquisitions to buy technology and new customer relationships, while founders and early investors in high‑growth fintechs are being introduced to the concept of “downside scenarios” the hard way.

In the primary markets, the pipeline for initial public offerings on the New York Stock Exchange and Nasdaq remained active but selective, with investors showing renewed interest in companies tied to AI and chips while maintaining a more cautious stance toward businesses that lack clear profitability paths. Activity continued to be shaped by the same calculus that has dominated since the last cycle’s froth faded: firms with strong cash flows, defensible niches, or direct links to AI and data infrastructure can find a receptive audience, while others are encouraged—politely—to wait for better conditions.

Closing perspective

Taken together, the week ending January 23, 2026, offered a familiar but still engrossing script: equity indexes grinding lower even as certain themes—AI hardware, weight‑loss and oncology drugs, safe‑haven metals—enjoyed star billing. The market, it seems, remains perfectly capable of worrying about tariffs, Greenland, inflation, and earnings all at once, even as investors continue to pay up for growth stories that promise to turn today’s volatility into tomorrow’s compounded returns.

Vista Partners Watchlist Updates

Modular Medical, Inc. (Nasdaq: MODD., $.4667), a leader in innovative insulin delivery technology targeting the $3 billion adult “almost-pumpers” diabetes market with user-friendly, affordable patch pumps, announced (Dec. 10) that it had priced an underwritten public offering (the “offering”) of 12,173,000 shares of its common stock and accompanying warrants to purchase 6,086,500 shares of its common stock. Each two shares of common stock are being offered and sold together with one accompanying warrant at a combined offering at a price of $0.77, yielding an effective price of $0.38 per share and $0.01 per warrant. The warrants will have an exercise price of $0.45 per share, are exercisable immediately upon issuance and will expire five years following the date of issuance. In connection with the offering, Modular Medical has granted the underwriter a 30-day option to purchase up to an additional 15% of common shares and/or warrants at the public offering price, less underwriting discounts and commissions. The over-allotment option may be elected with respect to, at the underwriter’s sole discretion, shares and warrants together, solely shares, solely warrants, or any combination thereof. Newbridge Securities Corporation is acting as the sole bookrunner for the offering. Assuming no exercise of the over-allotment option, the gross proceeds to the Company from the offering are expected to be approximately $4.68 million, before deducting underwriting discounts, commissions, and estimated offering expenses payable by the Company. The Company intends to use the net proceeds from the offering to fund operations and for working capital and general corporate purposes, including capital expenditures.

On Nov. 17, Modular announced Institutional Review Board (“IRB”) approval to conduct an in-house study of its next-generation Pivot™ insulin delivery system using insulin on people with diabetes (the “Study”). Pursuant to U.S. Food and Drug Administration (“FDA”) regulations, an IRB is a group that has been formally designated to review and monitor biomedical research involving human subjects. The Study will simulate real-world conditions by delivering insulin to adult participants to gather critical data on device function and usability and obtain user feedback. Modular Medical’s Pivot tubeless patch pump aims to enhance accessibility for underserved patients with diabetes and drive market penetration and expansion.

On Nov. 14, Modular Medical announced the 510(k) premarket submission of its next generation Pivot™ tubeless patch pump to the U.S. Food and Drug Administration (the “FDA”). The Company expects to commence the commercial launch of its Pivot pump in Q1 2026. On Nov. 3, Modular Medical the successful validation of its Pivot controller line, a critical milestone in preparing for the commercial launch of its Pivot patch pump targeted for Q1 2026. The Pivot controller line validation further demonstrates manufacturing readiness for high-volume production, positioning Modular Medical to meet the growing demand in the diabetes treatment market for advanced technology.

Eupraxia Pharmaceuticals Inc. (NASDAQ: EPRX, $9, up 2.62% over the last 5-days), a clinical-stage biotechnology company leveraging its proprietary Diffusphere™ technology to optimize local, controlled drug delivery for diseases with significant unmet need, announced (Nov. 13) the second set of 52-week follow up data from its ongoing Phase 1b/2a RESOLVE trial evaluating a single administration EP-104GI for the treatment of eosinophilic esophagitis (“EoE”). James A. Helliwell, Chief Executive Officer of Eupraxia stated,“These data further highlight the strong durability and tolerability profile of EP-104GI, reinforcing its potential to become a convenient, once-a-year treatment that fits seamlessly into routine disease management by aligning with annual patient endoscopies. The Cohorts 5 & 6 patients – the only groups to have reached 52 weeks in the trial – are demonstrating levels of symptom relief that is durable and clinically meaningful – we are very encouraged by this outcome. We’re also pleased that our previously announced 52-week data were presented as a late-breaking presentation at the American College of Gastroenterology Annual Scientific Meeting (ACG). These new results build on that momentum. Given that current EoE therapies often struggle with long-term adherence, we believe a durable, once-yearly treatment could meaningfully improve patient outcomes and establish EP-104GI as a preferred option for both physicians and their patients.”

GeoVax Labs, Inc. (Nasdaq: GOVX, $3.15, +10.53% over the last 5-days), a clinical-stage biotechnology company developing multi-antigen vaccines and immunotherapies for infectious diseases and cancer.

GeoVax is heading into the 44th Annual J.P. Morgan Healthcare Conference week (“JPM2026”) in San Francisco, CA Jan. 12-15 with the kind of narrative biotech investors typically like to hear: a differentiated platform, large funded trials lining up, and multiple shots on goal in both infectious disease and oncology. The company is leaning into its MVA platform as a potential franchise engine rather than a one‑product science experiment. Specifically, investors can meet David Dodd, Chairman & CEO of GeoVax, during his presentation at the Hilton Union Square, 333 O’Farrell Street, Yosemite A (Ballroom Level), San Francisco, CA on January 13, 2026, 2:30 pm PST.

GeoVax announced (Dec. 19) that it has entered into definitive securities purchase agreements with several institutional and individual investors for the purchase and sale of approximately 13.2 million units, each comprised of one share of the Company’s common stock and warrants, as described below, to purchase shares of the Company’s common stock, at a price of $0.245 per unit in a public offering. The Company will issue warrants to purchase up to approximately 26.5 million shares of common stock. The warrants will have an exercise price of $0.245 per share, will be exercisable immediately following the date of issuance and will have a term of five years following the date of issuance. Roth Capital Partners is acting as the exclusive placement agent for the offering. The gross proceeds to the Company from this offering are expected to be approximately $3.2 million, before deducting the placement agent’s fees and other offering expenses payable by the Company. The Company intends to use the net proceeds from this offering for working capital and general corporate purposes. The closing of the offering is expected to occur on or about December 22, 2025, subject to the satisfaction of customary closing conditions.

GeoVax announced (Dec. 18) the publication of a peer-reviewed article in Frontiers in Immunology titled: “Multi-antigen MVA-vectored SARS-CoV-2 vaccine, GEO-CM04S1, induces cross-protective immune responses to ancestral and Omicron variants.” The study provides definitive preclinical evidence that GeoVax’s multi-antigen COVID-19 vaccine candidate, GEO-CM04S1, delivers full cross-variant protection, driven predominantly by robust T-cell responses, even in the absence of neutralizing antibodies. The findings reinforce the design philosophy behind GeoVax’s MVA-based, multi-antigen platform and provide mechanistic insight that is increasingly relevant for immunocompromised individuals, who often fail to respond optimally to the first-generation COVID-19 vaccines.

GeoVax announced (Dec. 17) the successful completion of fill-finish for the initial clinical batch of GEO-MVA, its next-generation Mpox/smallpox vaccine. The product has now entered final release evaluation, the concluding quality-control and compliance process required before shipment for clinical use, positioning the Company for Phase 3 immunobridging trial start-up activities in Q1 2026. Fill-finish – the sterile, cGMP-regulated process of filling, sealing, and packaging vaccine vials – marks the last manufacturing step before a vaccine may enter clinical study supply channels. With fill-finish complete and GEO-MVA now undergoing final release evaluation, GeoVax has moved into the final pre-clinical-deployment phase of its EMA-aligned clinical program. In June 2025, the European Medicines Agency (EMA) Scientific Advice confirmed that a single Phase 3 immunobridging study demonstrating immune comparability to the approved MVA vaccine, Imvanex(R), would be sufficient to evaluate GEO-MVA’s efficacy. This provides a clear, accelerated regulatory path to licensure. This milestone coincides with increasing Mpox activity globally – including expanding Clade I outbreaks in Africa and emerging cases in the United States – exposing vulnerabilities associated with global dependence on a sole foreign MVA vaccine supplier. GEO-MVA is designed to expand supply, diversify sources, and strengthen biodefense infrastructure.

Volato Group, Inc. (NYSE American: SOAR, $.49) and M2i Global, Inc. (MTWO, $.0485), a company specializing in the development and execution of a complete global value supply chain for critical minerals, reaffirmed, on Tuesday, Jan. 20, their expectation to complete their targeted first-quarter 2026 closing timeline for the previously announced business combination, citing steady advancement through the SEC review process alongside continued progress in operational planning and integration readiness. Subject to the effectiveness of the registration statement on Form S-4, stockholder approvals, and other customary closing conditions, the companies continue to expect the merger to close in the first quarter of 2026. To align the transaction timeline with the current stage of the SEC review process, the companies have mutually agreed to extend the end date of the merger agreement through March 31, 2026. This extension reflects disciplined execution and provides additional runway to complete the remaining regulatory steps in an orderly manner, while maintaining transaction commitment and protecting stockholder interests. Amendment No. 1 to the Form S-4 was filed on Monday, January 12, 2026, to respond to SEC comments and advance the registration statement through the review process. The review timeline was affected in part by a temporary slowdown in SEC operations following the recent federal government shutdown. With the amendment now on file, the companies are focused on completing the remaining steps of the SEC review process.

On Jan. 9, M2i Global and Volato Group announced that they have entered into a strategic collaboration agreement with Australian company Titanium X to advance critical mineral development in the US. This partnership represents a significant move towards enhancing domestic refining capacity and strengthening the critical materials supply chain that underpins US industry and national security. Titanium X and M2i Global will work together on the financing, development and commercialisation of the former’s critical mineral assets. M2i Global will apply its global experience in delivering mineral projects to support these initiatives. The companies are also in talks to conclude an exclusive titanium concentrate supply agreement.

On Jan. 7, M2i Global, Inc. (MTWO , $,05) along with Volato Group, Inc. (NYSE American: SOAR, $.45), a technology-driven company, announced a strategic collaboration agreement with Titanium X, marking a major step forward in advancing domestic refining capabilities and securing the critical materials supply chain essential to U.S. industry and national security.

Volato Group, Inc. today (Dec. 29) announced the appointment of Alan D. Gaines to its Board of Directors, effective immediately. Mr. Gaines will also serve as Chairman of the Audit Committee.

On Dec. 23, Volato Group, Inc. announced preliminary financial guidance for the fourth quarter and full year ending December 31, 2025, reflecting continued execution against its strategic and balance sheet objectives. For the fourth quarter of 2025, Volato expects to report revenue between $27 million and $28 million. For the full year 2025, the Company anticipates total revenue between $78 million and $79 million, with net income of $6 million to $8 million. These results reflect a year of meaningful progression aligning operational performance with Volato’s long-term growth initiatives and advancing its pending merger with M2i Global, Inc. (OTC: MTWO). During 2025, Volato also made substantial progress strengthening its balance sheet. As of September 30, 2025, the Company reduced total liabilities to $9.5 million, satisfying the debt reduction condition required under its pending merger agreement with M2i Global, Inc. (OTC: MTWO). Volato expects continued improvement in its capital structure as it advances toward a targeted first-quarter 2026 closing of the transaction. “Our 2025 results reflect a year of transformation and disciplined balance sheet execution,” said Mark Heinen, Chief Financial Officer of Volato. “We made significant progress reducing liabilities while sharpening our focus on scalable, technology-driven businesses that are designed to complement and strengthen the M2i Global platform over the long term.”

Serina Therapeutics (NYSE American: SER, $2.87), Alabama-based biotech is betting its proprietary POZ platform and reimagined approach to apomorphine delivery may redefine the treatment paradigm for patients who have exhausted standard oral therapies. On Dec. 11, Serina announced the appointment of Joshua Thomas, Ph.D., as Vice President and Head of Chemistry. He will oversee internal and external chemistry efforts to optimize POZ-based candidates, supporting efficient translation from discovery through development.

On Dec. 10, Serina announced that it has submitted a complete response to the U.S. Food and Drug Administration’s (“FDA”) clinical hold letter for SER-252, the Company’s lead program for advanced Parkinson’s disease. As previously disclosed, the FDA placed the Company’s Investigational New Drug (“IND”) application for SER-252 on clinical hold pending additional information related to a commonly used formulation excipient. On November 25, 2025, the FDA issued a formal full clinical hold letter specifying the information required to permit initiation of the planned Phase 1b registrational study, SER-252-1b. The issues identified by the FDA do not relate to the apomorphine active drug substance, its mechanism of action, the use of the enFuse device (Enable Injections) or the broader 505(b)(2) NDA development pathway previously discussed with the Agency.

The InterGroup Corporation (NASDAQ: INTG, $29.87, +1.67%) announced (Jan. 6) that on December 29, 2025, it completed the sale of a non-core 12-unit apartment complex in Los Angeles County for a gross sales price of approximately $4,850,000. InterGroup expects to report a GAAP net gain on sale of approximately $3,509,000, which will be reflected in the Company’s Form 10‑Q for the quarter ended December 31, 2025. The transaction is expected to result in federal and state income tax liability, the amount of which will be determined based on the Company’s final tax position and applicable tax rules.

DoubleVerify Holdings Inc. (DV) closed at $10.99, +4.07% over the last 5-days. DoubleVerify, which built its franchise on media verification and ad performance analytics, is now the first badged TikTok Marketing Partner focused specifically on attention measurement, tapping impression-level signals from the platform. Brands gain a granular view of how exposure and user interaction come together across TikTok formats, ad sets, creatives, and objectives, effectively treating every swipe as a tiny A/B test.

flyExclusive, Inc. (NYSE American: FLYX, $3.28), one of the nation’s largest private jet operators and a certified Part 145 Repair Station, today announced it has signed an authorized dealership agreement with Starlink, becoming a certified dealer and installer for Starlink’s high-speed, low-latency aviation connectivity system.

The Sources

1. Wall Street Journal – “Stock Market Today: Dow Drops; Intel Stock Slides; Gold Hits Record”
   https://www.wsj.com/livecoverage/stock-market-today-dow-sp-500-nasdaq-01-23-2026[wsj]​
2. Bloomberg – “S&P 500 Steady at End of Turbulent Week; Intel Sinks on Earnings”
   https://www.bloomberg.com/news/articles/2026-01-23/us-stocks-slip-at-end-of-turbulent-week-intel-sinks-on-earnings[bloomberg]​
3. Bloomberg – “S&P 500 Posts Its First Two-Week Losses Since June: Markets Wrap”
   https://www.bloomberg.com/news/articles/2026-01-22/stock-market-today-dow-s-p-live-updates[bloomberg]​
4. Yahoo Finance – “Stock market today: Dow, S&P 500, Nasdaq rise after Trump backpedals on tariffs”
   https://finance.yahoo.com/news/stock-market-today-dow-sp-500-nasdaq-futures-rise-after-trump-backpedals-on-tariffs-234947394.html[uk.finance.yahoo]​
5. Reuters – “Wall Street finishes up as investors buoyed by tariff relief, upbeat data”
   https://www.reuters.com/world/europe/futures-rise-further-greenland-relief-2026-01-22/[reuters]​
6. New York Times – “Stocks Rebound After Trump Backs Off European Tariffs”
   https://www.nytimes.com/2026/01/21/business/greenland-stocks-bonds-dollar-gold.html[nytimes]​
7. U.S. News & World Report – “US Stocks Recover Half of the Prior Day’s Plunge After Trump Calls off Greenland-Related Tariffs”
   https://www.usnews.com/news/business/articles/2026-01-20/us-stocks-recover-half-of-the-prior-days-plunge-after-trump-calls-off-greenland-related-tariffs[usnews]​
8. Investopedia – “Markets News, Jan. 22, 2026: Stocks Finish Higher for 2nd Straight Day”
   https://www.investopedia.com/dow-jones-today-01222026-11890213[investopedia]​
9. Investors.com – “Dow Falls While Nasdaq Is The Day’s Bright Spot (Live Coverage)”
   https://www.investors.com/market-trend/stock-market-today/dow-jones-sp500-nasdaq-greenland-deal-intel-stock-intc/[investors]​
10. Investors.com – “Stock Market Falls, Recovers On Trump Greenland Shift” (Weekly Review)
    https://www.investors.com/news/stock-market-falls-recovers-on-trumps-greenland-shifts-intel-netflix-tesla-key-movers-weekly-review/[investors]​
11. CNBC – “5 things to know before the stock market opens Friday” (Jan. 23, 2026)
    https://www.cnbc.com/2026/01/23/5-things-to-know-before-the-stock-market-opens.html[cnbc]​
12. CNBC – “Stock market news for Jan. 23, 2026 – live updates”
    https://www.cnbc.com/2026/01/22/stock-market-today-live-updates.html[cnbc]​
13. Trading Economics – “United States Economic Calendar”
    https://tradingeconomics.com/united-states/calendar[tradingeconomics]​
14. Investing.com – “7 Critical Signals From This Week’s U.S. Economic Calendar (January 19–23, 2026)”
    https://in.investing.com/analysis/7-critical-signals-from-this-weeks-us-economic-calendar-january-1923-2026-200633925[in.investing]​
15. Yahoo Finance – Eli Lilly and Company (LLY) quote page
    https://finance.yahoo.com/quote/LLY/[finance.yahoo]​
16. Yahoo Finance – “Why Eli Lilly (LLY) Stock Is Up Today”
    https://finance.yahoo.com/news/why-eli-lilly-lly-stock-203040864.html[finance.yahoo]​
17. Motley Fool via AOL – “Eli Lilly Soared by 39% in 2025, but Here’s Another Healthcare Stock to Consider”
    https://www.aol.com/articles/eli-lilly-soared-39-2025-103000224.html[aol]​
18. MarketBeat – “Strs Ohio Sells 46,646 Shares of Eli Lilly and Company (LLY)”
    https://www.marketbeat.com/instant-alerts/filing-strs-ohio-sells-46646-shares-of-eli-lilly-and-company-lly-2026-01-23/[marketbeat]​
19. Investor’s Business Daily – “Eli Lilly Stock Rebounds As Weight-Loss Drug Battle Continues”
    https://www.investors.com/stock-lists/sector-leaders/eli-lilly-stock-lly-orforglipron-weight-loss-drugs/[investors]​
20. Globe and Mail – “4 Leading Tech Stocks to Buy in 2026”
    https://www.theglobeandmail.com/investing/markets/markets-news/Motley%20Fool/36954814/4-leading-tech-stocks-to-buy-in-2026/[theglobeandmail]​
21. MarketBeat – “Best Technology Stocks To Consider – January 5th”
    https://www.marketbeat.com/instant-alerts/best-technology-stocks-to-consider-january-5th-2026-01-05/[marketbeat]​
22. Global X ETFs – “The Next Big Theme: January 2026”
    https://www.globalxetfs.com/articles/the-next-big-theme-january-2026[globalxetfs]​
23. Nasdaq.com – “Pre-Markets Lower Ahead of Massive Polar Vortex”
    https://www.nasdaq.com/articles/pre-markets-lower-ahead-massive-polar-vortex[nasdaq]​
24. CNBC – “Biggest Wall Street analyst calls Thursday like Nvidia”
    https://www.cnbc.com/2026/01/15/biggest-wall-street-analyst-calls-thursday-like-nvidia.html[cnbc]​
25. Yahoo Finance – “High Growth US Tech Stocks To Watch In January 2026”
    https://finance.yahoo.com/news/high-growth-us-tech-stocks-113827833.html[finance.yahoo]​
26. Yahoo Finance – “Oil Ticks Up as Trump Cites ‘Framework’ for Greenland Deal”
    https://finance.yahoo.com/news/oil-drops-traders-gear-trump-060219587.html[finance.yahoo]​

Wall Street ended Thursday with a relieved shrug and a raised eyebrow, as President Trump’s tariff U‑turn kept risk appetites intact and sent major indexes modestly higher while safe‑haven trades stayed stubbornly in vogue. On balance, Thursday’s tape also suggested a market willing to forgive colorful tariff diplomacy as long as the actual tariffs stay mostly hypothetical, central banks remain predictable, and AI stocks keep justifying their starring roles—proof that in 2026, Wall Street still prefers drama in earnings calls, not customs forms.

Major indexes

• S&P 500: The S&P 500 added about 0.55%, extending Wednesday’s rebound after the White House formally backed away from sweeping tariffs on eight European nations tied to the Greenland saga, leaving the benchmark within sight of record territory.
• Dow 30: The Dow Jones Industrial Average also climbed roughly 0.63%, with cyclicals and big tech sharing the load as investors treated the tariff reprieve as an excuse to rotate back into economically sensitive names rather than hide in cash.
• Nasdaq: The Nasdaq Composite led with a gain of about 0.91%, powered by AI‑heavyweights and chipmakers as traders re‑embraced the “everything AI, all at once” trade that had briefly gone out of fashion when tariff headlines flared.
• Russell 2000: Small caps continued their early‑year resurgence rising .76%, with the Russell 2000 building on a string of record closes and extending a stretch of outperformance versus the Nasdaq and S&P 500 that strategists note is rare this late in a cycle.

Macro and policy

• Tariffs and trade: The administration formally paused plans for 10% across‑the‑board tariffs on imports from Denmark, Norway, Sweden, France, Germany, the UK, the Netherlands and Finland after a “framework” understanding on Greenland, removing an imminent shock to transatlantic trade even as broader tariff policy remains the market’s favorite recurring nightmare. Separately, new 25% Section 232 tariffs on certain advanced semiconductor imports underscore that while the Greenland front has cooled, chip geopolitics remain very much a live fire exercise.
• FOMC and rates: The Federal Reserve’s next policy gathering is scheduled for Jan. 27–28, with markets pricing a steady hand next week and hoping mostly for clarity on the timing and pace of eventual rate cuts rather than any surprise hawkish flourish. The 10‑year Treasury yield has recently hovered in the mid‑4% range while the 30‑year sits just under 4.9%, leaving the curve still relatively flat by historical standards rather than deeply inverted.
• Shutdown watch: On Capitol Hill, lawmakers are racing a Jan. 30 funding deadline, with a 1,000‑plus‑page bipartisan spending package on the table designed to avert a repeat of last year’s record‑long shutdown; markets are treating brinkmanship as background noise but would likely notice quickly if talks stall.
• Reuters reported that the gross domestic product increased at an upwardly revised ‌4.4% annualized rate, the fastest pace since the third quarter of 2023, the Commerce Department’s Bureau of Economic Analysis said in its updated estimate of third-quarter GDP on Thursday.

Commodities and crypto

• Gold and silver: Gold prices pushed to fresh record highs above roughly $4,938.40 per troy ounce at one point, reflecting lingering anxiety about tariffs, fiscal politics and long‑term currency credibility even on a day when equities were in a decent mood. Silver continued to ride a powerful structural bull story rising to $96.21/oz. tied to industrial demand and tightening supply, with recent gains far outpacing gold on a percentage basis.
• Oil: Crude oil futures slipped around 1.57% to $59.67, with prices consolidating as traders weighed resilient demand against concerns that policy and tariff uncertainty could eventually sap global growth; technically, crude remains in a choppy range rather than a clean trend.
• Bitcoin: Bitcoin hovered near the psychologically loaded $90,000 level after a sharp pullback from its prior peak near $126,000, behaving less like “digital gold” and more like a levered expression of risk sentiment that is currently catching its breath.

Corporate news and key stocks

• Eli Lilly (LLY): Eli Lilly extended its climb as investors continued to chase the obesity‑drug leader; shares traded around the low‑$1,080s intraday, up modestly and hovering near 52‑week highs, helped by strong GLP‑1 demand, upbeat clinical updates and expectations for an oral obesity therapy launch later this year. In a market increasingly obsessed with weight‑loss injections, Lilly remains the stock that rarely goes on a valuation diet.
• Semiconductors – TSM, NVIDIA ($184.84, +.91%, Micron (MU, $397.58, +2.18%), Intel (INTC, $54.3), Broadcom: Semiconductor names were again central to the AI trade narrative. Micron rallied on the back of a strong earnings print and bullish commentary around high‑bandwidth memory demand, underscoring how memory chips have migrated from commodity backwater to AI royalty. NVIDIA remained a core beneficiary of AI infrastructure spending, staying in investors’ good graces as one of the market’s most recommended large‑cap tech names. Intel, despite warnings that its AI enthusiasm may be outrunning fundamentals, participated in the broader chip bid rose to $54.32, however has dropped significantly in the aftermarket as their Q1 failed to impress. Taiwan Semiconductor and Broadcom traded as essential plumbing for the same AI and cloud cycle, with tariff headlines particularly relevant given Washington’s new semiconductor‑focused trade restrictions.
• Megacap platforms – Apple, Tesla, Meta: Apple shares stayed supported, with the stock still broadly rated in “buy” territory as investors look past smartphone cyclicality toward services and AI‑enhanced devices. Tesla (TSLA, $449.36. +4.15%)remained a volatility magnet at the intersection of EV adoption and Musk‑driven narrative swings, participating in the tech rally as traders leaned back into higher‑beta AI and EV names. Meta Platforms (META, $647.63, +5.66%) added to 2025’s recovery as markets rewarded its cash‑gushing ad engine and AI ambitions, even as regulators continue to lurk in the wings.
• Nokia: Nokia (NOK) stayed a more subdued story rising +.93% to $6.50, with the once‑iconic handset leader now trading as a network and infrastructure play that tends to move more on capex cycles and 5G spending than on the day‑to‑day theatrics of AI headlines.
• McDonald’s: McDonald’s shares edged higher to $306.03 as the chain benefited from its role as a defensive, cash‑flow machine in a world where diners may trade down from white‑tablecloth to drive‑through but rarely skip lunch entirely.
• Rio Tinto: Rio Tinto traded in step with industrial metals sentiment, with investors parsing how tariff uncertainty and global growth forecasts might influence demand for iron ore and other key inputs; the stock today functioned as something of a barometer for how seriously markets take the risk of a renewed trade slowdown.
• Oracle: Oracle (ORCL, $178.18, +2.47%) continued to ride enthusiasm around cloud infrastructure and database demand, offering investors a lower‑drama, high‑cash‑conversion way to play the same digital transformation themes driving the AI darlings.
• OKLO: OKLO, a small‑scale nuclear and advanced reactor story, remained a speculative vehicle tethered to the broader decarbonization theme, with sentiment sensitive to news on regulatory milestones and funding rather than near‑term earnings closed at $90.93, +.17%.
• Palantir Technologies: Palantir closed up modestly after a blistering 2025 that saw the stock gain roughly 145%, as some on the Street warned that expectations for its AI platforms and government contracts have become rich enough to require immaculate execution. The company remains at the center of the AI‑plus‑national‑security narrative, but buyers are becoming more discerning on price.

Deals, listings and other market color

• M&A and SPACs: In energy and climate tech, General Fusion announced a definitive agreement to go public via a merger with Spring Valley Acquisition Corp. III, in a deal valuing the fusion company at roughly $1 billion and positioning it to list on Nasdaq under the ticker GFUZ once the transaction closes. The market’s appetite for fusion‑powered dreams appears to remain intact, at least on the term‑sheet level. Capital One Financial Corporation (NYSE: COF, $235.07, +1.76%) today announced that it has entered into a definitive agreement to acquire Brex, in a combination of stock and cash transaction valued at $5.15 billion. Brex is a modern, AI-native software platform offering intelligent finance solutions that make it easy for businesses to issue corporate cards, automate expense management and make secure, real-time payments. The company also leverages AI agents to help customers automate complex workflows to reduce manual review and control spend.
• IPOs: In the traditional IPO lane, Praetorian Acquisition Corp. priced a $220 million SPAC offering of 22 million units at $10 each, with trading on Nasdaq as PTORU expected to begin tomorrow, Jan. 23, another reminder that blank‑check vehicles, while no longer the life of the party, still find occasional invitations. A separate $200 million SPAC, X3 Acquisition Corp. Ltd., also recently closed its initial public offering, adding more dry powder to the market’s deal‑making arsenal.

Vista Partners Watchlist Updates

Modular Medical, Inc. (Nasdaq: MODD., $.4705), a leader in innovative insulin delivery technology targeting the $3 billion adult “almost-pumpers” diabetes market with user-friendly, affordable patch pumps, announced (Dec. 10) that it had priced an underwritten public offering (the “offering”) of 12,173,000 shares of its common stock and accompanying warrants to purchase 6,086,500 shares of its common stock. Each two shares of common stock are being offered and sold together with one accompanying warrant at a combined offering at a price of $0.77, yielding an effective price of $0.38 per share and $0.01 per warrant. The warrants will have an exercise price of $0.45 per share, are exercisable immediately upon issuance and will expire five years following the date of issuance. In connection with the offering, Modular Medical has granted the underwriter a 30-day option to purchase up to an additional 15% of common shares and/or warrants at the public offering price, less underwriting discounts and commissions. The over-allotment option may be elected with respect to, at the underwriter’s sole discretion, shares and warrants together, solely shares, solely warrants, or any combination thereof. Newbridge Securities Corporation is acting as the sole bookrunner for the offering. Assuming no exercise of the over-allotment option, the gross proceeds to the Company from the offering are expected to be approximately $4.68 million, before deducting underwriting discounts, commissions, and estimated offering expenses payable by the Company. The Company intends to use the net proceeds from the offering to fund operations and for working capital and general corporate purposes, including capital expenditures.

On Nov. 17, Modular announced Institutional Review Board (“IRB”) approval to conduct an in-house study of its next-generation Pivot™ insulin delivery system using insulin on people with diabetes (the “Study”). Pursuant to U.S. Food and Drug Administration (“FDA”) regulations, an IRB is a group that has been formally designated to review and monitor biomedical research involving human subjects. The Study will simulate real-world conditions by delivering insulin to adult participants to gather critical data on device function and usability and obtain user feedback. Modular Medical’s Pivot tubeless patch pump aims to enhance accessibility for underserved patients with diabetes and drive market penetration and expansion.

On Nov. 14, Modular Medical announced the 510(k) premarket submission of its next generation Pivot™ tubeless patch pump to the U.S. Food and Drug Administration (the “FDA”). The Company expects to commence the commercial launch of its Pivot pump in Q1 2026. On Nov. 3, Modular Medical the successful validation of its Pivot controller line, a critical milestone in preparing for the commercial launch of its Pivot patch pump targeted for Q1 2026. The Pivot controller line validation further demonstrates manufacturing readiness for high-volume production, positioning Modular Medical to meet the growing demand in the diabetes treatment market for advanced technology.

Eupraxia Pharmaceuticals Inc. (NASDAQ: EPRX, $9.01), a clinical-stage biotechnology company leveraging its proprietary Diffusphere™ technology to optimize local, controlled drug delivery for diseases with significant unmet need, announced (Nov. 13) the second set of 52-week follow up data from its ongoing Phase 1b/2a RESOLVE trial evaluating a single administration EP-104GI for the treatment of eosinophilic esophagitis (“EoE”). James A. Helliwell, Chief Executive Officer of Eupraxia stated,“These data further highlight the strong durability and tolerability profile of EP-104GI, reinforcing its potential to become a convenient, once-a-year treatment that fits seamlessly into routine disease management by aligning with annual patient endoscopies. The Cohorts 5 & 6 patients – the only groups to have reached 52 weeks in the trial – are demonstrating levels of symptom relief that is durable and clinically meaningful – we are very encouraged by this outcome. We’re also pleased that our previously announced 52-week data were presented as a late-breaking presentation at the American College of Gastroenterology Annual Scientific Meeting (ACG). These new results build on that momentum. Given that current EoE therapies often struggle with long-term adherence, we believe a durable, once-yearly treatment could meaningfully improve patient outcomes and establish EP-104GI as a preferred option for both physicians and their patients.”

GeoVax Labs, Inc. (Nasdaq: GOVX, $2.88), a clinical-stage biotechnology company developing multi-antigen vaccines and immunotherapies for infectious diseases and cancer.

GeoVax is heading into the 44th Annual J.P. Morgan Healthcare Conference week (“JPM2026”) in San Francisco, CA Jan. 12-15 with the kind of narrative biotech investors typically like to hear: a differentiated platform, large funded trials lining up, and multiple shots on goal in both infectious disease and oncology. The company is leaning into its MVA platform as a potential franchise engine rather than a one‑product science experiment. Specifically, investors can meet David Dodd, Chairman & CEO of GeoVax, during his presentation at the Hilton Union Square, 333 O’Farrell Street, Yosemite A (Ballroom Level), San Francisco, CA on January 13, 2026, 2:30 pm PST.

GeoVax announced (Dec. 19) that it has entered into definitive securities purchase agreements with several institutional and individual investors for the purchase and sale of approximately 13.2 million units, each comprised of one share of the Company’s common stock and warrants, as described below, to purchase shares of the Company’s common stock, at a price of $0.245 per unit in a public offering. The Company will issue warrants to purchase up to approximately 26.5 million shares of common stock. The warrants will have an exercise price of $0.245 per share, will be exercisable immediately following the date of issuance and will have a term of five years following the date of issuance. Roth Capital Partners is acting as the exclusive placement agent for the offering. The gross proceeds to the Company from this offering are expected to be approximately $3.2 million, before deducting the placement agent’s fees and other offering expenses payable by the Company. The Company intends to use the net proceeds from this offering for working capital and general corporate purposes. The closing of the offering is expected to occur on or about December 22, 2025, subject to the satisfaction of customary closing conditions.

GeoVax announced (Dec. 18) the publication of a peer-reviewed article in Frontiers in Immunology titled: “Multi-antigen MVA-vectored SARS-CoV-2 vaccine, GEO-CM04S1, induces cross-protective immune responses to ancestral and Omicron variants.” The study provides definitive preclinical evidence that GeoVax’s multi-antigen COVID-19 vaccine candidate, GEO-CM04S1, delivers full cross-variant protection, driven predominantly by robust T-cell responses, even in the absence of neutralizing antibodies. The findings reinforce the design philosophy behind GeoVax’s MVA-based, multi-antigen platform and provide mechanistic insight that is increasingly relevant for immunocompromised individuals, who often fail to respond optimally to the first-generation COVID-19 vaccines.

GeoVax announced (Dec. 17) the successful completion of fill-finish for the initial clinical batch of GEO-MVA, its next-generation Mpox/smallpox vaccine. The product has now entered final release evaluation, the concluding quality-control and compliance process required before shipment for clinical use, positioning the Company for Phase 3 immunobridging trial start-up activities in Q1 2026. Fill-finish – the sterile, cGMP-regulated process of filling, sealing, and packaging vaccine vials – marks the last manufacturing step before a vaccine may enter clinical study supply channels. With fill-finish complete and GEO-MVA now undergoing final release evaluation, GeoVax has moved into the final pre-clinical-deployment phase of its EMA-aligned clinical program. In June 2025, the European Medicines Agency (EMA) Scientific Advice confirmed that a single Phase 3 immunobridging study demonstrating immune comparability to the approved MVA vaccine, Imvanex(R), would be sufficient to evaluate GEO-MVA’s efficacy. This provides a clear, accelerated regulatory path to licensure. This milestone coincides with increasing Mpox activity globally – including expanding Clade I outbreaks in Africa and emerging cases in the United States – exposing vulnerabilities associated with global dependence on a sole foreign MVA vaccine supplier. GEO-MVA is designed to expand supply, diversify sources, and strengthen biodefense infrastructure.

Volato Group, Inc. (NYSE American: SOAR, $.49) and M2i Global, Inc. (MTWO, $.0485), a company specializing in the development and execution of a complete global value supply chain for critical minerals, reaffirmed, on Tuesday, Jan. 20, their expectation to complete their targeted first-quarter 2026 closing timeline for the previously announced business combination, citing steady advancement through the SEC review process alongside continued progress in operational planning and integration readiness. Subject to the effectiveness of the registration statement on Form S-4, stockholder approvals, and other customary closing conditions, the companies continue to expect the merger to close in the first quarter of 2026. To align the transaction timeline with the current stage of the SEC review process, the companies have mutually agreed to extend the end date of the merger agreement through March 31, 2026. This extension reflects disciplined execution and provides additional runway to complete the remaining regulatory steps in an orderly manner, while maintaining transaction commitment and protecting stockholder interests. Amendment No. 1 to the Form S-4 was filed on Monday, January 12, 2026, to respond to SEC comments and advance the registration statement through the review process. The review timeline was affected in part by a temporary slowdown in SEC operations following the recent federal government shutdown. With the amendment now on file, the companies are focused on completing the remaining steps of the SEC review process.

On Jan. 9, M2i Global and Volato Group announced that they have entered into a strategic collaboration agreement with Australian company Titanium X to advance critical mineral development in the US. This partnership represents a significant move towards enhancing domestic refining capacity and strengthening the critical materials supply chain that underpins US industry and national security. Titanium X and M2i Global will work together on the financing, development and commercialisation of the former’s critical mineral assets. M2i Global will apply its global experience in delivering mineral projects to support these initiatives. The companies are also in talks to conclude an exclusive titanium concentrate supply agreement.

On Jan. 7, M2i Global, Inc. along with Volato Group, Inc. (“Volato”) (NYSE American: SOAR), a technology-driven company, announced a strategic collaboration agreement with Titanium X, marking a major step forward in advancing domestic refining capabilities and securing the critical materials supply chain essential to U.S. industry and national security.

Volato Group, Inc. today (Dec. 29) announced the appointment of Alan D. Gaines to its Board of Directors, effective immediately. Mr. Gaines will also serve as Chairman of the Audit Committee.

On Dec. 23, Volato Group, Inc. announced preliminary financial guidance for the fourth quarter and full year ending December 31, 2025, reflecting continued execution against its strategic and balance sheet objectives. For the fourth quarter of 2025, Volato expects to report revenue between $27 million and $28 million. For the full year 2025, the Company anticipates total revenue between $78 million and $79 million, with net income of $6 million to $8 million. These results reflect a year of meaningful progression aligning operational performance with Volato’s long-term growth initiatives and advancing its pending merger with M2i Global, Inc. (OTC: MTWO). During 2025, Volato also made substantial progress strengthening its balance sheet. As of September 30, 2025, the Company reduced total liabilities to $9.5 million, satisfying the debt reduction condition required under its pending merger agreement with M2i Global, Inc. (OTC: MTWO). Volato expects continued improvement in its capital structure as it advances toward a targeted first-quarter 2026 closing of the transaction. “Our 2025 results reflect a year of transformation and disciplined balance sheet execution,” said Mark Heinen, Chief Financial Officer of Volato. “We made significant progress reducing liabilities while sharpening our focus on scalable, technology-driven businesses that are designed to complement and strengthen the M2i Global platform over the long term.”

Serina Therapeutics (NYSE American: SER, $2.96, +3.86%), Alabama-based biotech is betting its proprietary POZ platform and reimagined approach to apomorphine delivery may redefine the treatment paradigm for patients who have exhausted standard oral therapies. On Dec. 11, Serina announced the appointment of Joshua Thomas, Ph.D., as Vice President and Head of Chemistry. He will oversee internal and external chemistry efforts to optimize POZ-based candidates, supporting efficient translation from discovery through development.

On Dec. 10, Serina announced that it has submitted a complete response to the U.S. Food and Drug Administration’s (“FDA”) clinical hold letter for SER-252, the Company’s lead program for advanced Parkinson’s disease. As previously disclosed, the FDA placed the Company’s Investigational New Drug (“IND”) application for SER-252 on clinical hold pending additional information related to a commonly used formulation excipient. On November 25, 2025, the FDA issued a formal full clinical hold letter specifying the information required to permit initiation of the planned Phase 1b registrational study, SER-252-1b. The issues identified by the FDA do not relate to the apomorphine active drug substance, its mechanism of action, the use of the enFuse device (Enable Injections) or the broader 505(b)(2) NDA development pathway previously discussed with the Agency.

The InterGroup Corporation (NASDAQ: INTG, $27.21) announced (Jan. 6) that on December 29, 2025, it completed the sale of a non-core 12-unit apartment complex in Los Angeles County for a gross sales price of approximately $4,850,000. InterGroup expects to report a GAAP net gain on sale of approximately $3,509,000, which will be reflected in the Company’s Form 10‑Q for the quarter ended December 31, 2025. The transaction is expected to result in federal and state income tax liability, the amount of which will be determined based on the Company’s final tax position and applicable tax rules.

DoubleVerify Holdings Inc. (DV) closed at $10.91, +3.71%. DoubleVerify, which built its franchise on media verification and ad performance analytics, is now the first badged TikTok Marketing Partner focused specifically on attention measurement, tapping impression-level signals from the platform. Brands gain a granular view of how exposure and user interaction come together across TikTok formats, ad sets, creatives, and objectives, effectively treating every swipe as a tiny A/B test.

flyExclusive, Inc. (NYSE American: FLYX, $3.26), one of the nation’s largest private jet operators and a certified Part 145 Repair Station, today announced it has signed an authorized dealership agreement with Starlink, becoming a certified dealer and installer for Starlink’s high-speed, low-latency aviation connectivity system.

The Sources

1. Wall Street overview and index moves
   https://www.wsj.com/livecoverage/stock-market-today-dow-sp-500-nasdaq-01-22-2026[wsj]​
2. U.S. stocks up on tariff relief and data
   https://www.reuters.com/world/europe/futures-rise-further-greenland-relief-2026-01-22/[reuters]​
3. U.S. and global markets after tariff U‑turn
   https://www.straitstimes.com/business/companies-markets/wall-street-ends-up-as-investors-buoyed-by-tariff-relief-upbeat-data[straitstimes]​
4. LA Times recap of tariff reversal and market reaction
   https://www.latimes.com/business/story/2026-01-22/stocks-climb-some-more-after-trump-calls-off-his-tariffs-for-greenland[latimes]​
5. Davos and the evolving trade map under Trump tariffs
   https://www.reuters.com/world/americas/new-trade-map-takes-shape-davos-world-adjusts-trump-tariffs-2026-01-22/[reuters]​
6. Davos tariffs discussion (alternative text version)
   https://amp.rte.ie/amp/1554506/[amp.rte]​
7. Tariff framework and Greenland context (background)
   https://www.asiaone.com/world/new-trade-map-takes-shape-davos-world-adjusts-trump-tariffs[asiaone]​
8. Trump tariff tracker and semiconductor‑related measures
   https://www.tradecomplianceresourcehub.com/2026/01/21/trump-2-0-tariff-tracker/tradecomplianceresourcehub+1
9. U.S. pauses proposed Greenland tariffs
   https://globalsanctions.com/2026/01/us-pauses-proposed-greenland-tariffs/[globalsanctions]​
10. Tech/AI rally – MU, NVDA, TSLA, etc.
    https://nai500.com/blog/2026/01/tech-rally-runs-hot-mu-nvda-googl-amzn-tsla-lead/[nai500]​
11. Small‑cap and Russell 2000 performance context
    https://www.morningstar.com/news/marketwatch/20260122169/small-cap-stocks-are-off-to-a-rare-bullish-start-history-says-tech-is-the-key[morningstar]​
12. Pre‑market macro and Fed expectations
    https://www.investopedia.com/5-things-to-know-before-the-stock-market-opens-january-22-2026-11890216[investopedia]​
13. Fed meeting calendar and policy schedule
    https://www.federalreserve.gov/monetarypolicy/fomccalendars.htm[federalreserve]​
14. U.S. 10‑year Treasury yield data
    https://fred.stlouisfed.org/series/DGS10[fred.stlouisfed]​
15. U.S. long‑bond yield levels
    https://tradingeconomics.com/united-states/30-year-bond-yield[tradingeconomics]​
16. Government funding bill and shutdown risk
    https://www.nbcnews.com/politics/congress/congress-releases-massive-funding-bill-ahead-shutdown-deadline-ice-cla-rcna254968[nbcnews]​
17. Shutdown backdrop and deadline overview
    https://ctmirror.org/2026/01/05/congress-federal-shutdown-january-2026/[ctmirror]​
18. Gold, silver and macro backdrop for 2026
    https://www.forbes.com/sites/digital-assets/2025/12/27/us-dollar-collapse-crisis-warning-2026-gold-and-silver-surge-predicted-to-continue/[forbes]​
19. Bitcoin evening technical and price update (22 Jan 2026)
    https://www.economies.com/crypto/analysis/evening-update-for-bitcoin–22-01-2026-124306[economies]​
20. Eli Lilly stock move and drivers
    https://finance.yahoo.com/news/why-eli-lilly-lly-stock-203040864.html[finance.yahoo]​
21. Eli Lilly pipeline and strategy context
    https://www.ainvest.com/news/eli-lilly-shares-rise-3-58-strategic-direction-pipeline-advancements-2601/[ainvest]​
22. Eli Lilly quote and intraday trading
    https://robinhood.com/us/en/stocks/LLY/[robinhood]​
23. Longer‑term Eli Lilly outlook
    https://247wallst.com/forecasts/2026/01/12/eli-lilly-lly-stock-price-prediction-and-forecast-2025-2030/[247wallst]​
24. Mega‑cap and AI/tech sentiment including NVDA, META, AAPL
    https://finance.yahoo.com/news/4-top-tech-stocks-buy-222000338.html[finance.yahoo]​
25. Recent trading in AAPL, NVDA, INTC and peers
    https://www.nasdaq.com/articles/after-hours-most-active-jan-20-2026-nflx-aapl-nvda-t-cccc-f-pfe-wmt-intc-gpn-path-nuvb[nasdaq]​
26. Caution on popular AI stocks including Palantir and Intel
    https://finance.yahoo.com/news/2-popular-ai-stocks-sell-024700655.html[finance.yahoo]​
27. Options activity around NVDA, INTC, TSLA and others
    https://theoptionsinsider.com/news/most-active-options/hotoptions-report-for-mid-day-january-21-2026-nvda-nflx-intc-tsla-amd-aapl-msft-mara-intu-pdd/[theoptionsinsider]​
28. Market‑wide news hub for Jan. 22, 2026 (sector and single‑stock notes)
    https://www.marketwatch.com/archive/2026/01/22[marketwatch]​
29. Trump Greenland tariff walk‑back and market color
    https://www.latimes.com/business/story/2026-01-22/stocks-climb-some-more-after-trump-calls-off-his-tariffs-for-greenland[latimes]​
30. General Fusion–Spring Valley Acquisition Corp. III SPAC merger
    https://finance.yahoo.com/news/general-fusion-become-first-publicly-130000859.html[finance.yahoo]​
31. Praetorian Acquisition Corp. $220M SPAC IPO (Nasdaq: PTORU)
    https://www.stocktitan.net/news/PTORU/praetorian-acquisition-corp-announces-the-pricing-of-220-000-000-hd4s2y4ipms9.html[stocktitan]​
32. X3 Acquisition Corp. $200M SPAC IPO
    https://www.stocktitan.net/news/XCBEU/x3-acquisition-corp-ltd-announces-closing-of-200-000-000-initial-sglx6durwxrc.html[stocktitan]​

U.S. stocks staged a confident rebound on Wednesday, January 21, 2026, as investors cheered President Donald Trump’s decision to shelve threatened tariffs tied to his Greenland ambitions, turning a geopolitical soap opera into a tradable relief rally that lifted risk assets across the board. The market treated the newly unveiled “framework” with NATO over Greenland’s future as sufficiently vague to be ignored on the spreadsheet but clear enough to justify buying the dip.

Major Indexes

The S&P 500 climbed roughly 1.16%, recouping a sizable chunk of Tuesday’s sharp losses as traders reversed defensive positioning and rotated back into large‑cap growth and AI bellwethers. The benchmark’s bounce followed one of its steepest single‑day drops in months, underscoring how quickly sentiment can swing when tariff threats morph into handshake agreements in Davos.

The Dow Jones Industrial Average advanced about 1.21%, helped by multinational industrials and financials that had been in the direct line of fire from prospective European tariffs. With the 10% levies on eight EU countries now on ice, investors resumed the familiar exercise of paying up for earnings visibility while hoping the next presidential post does not rewrite their models overnight.

The tech‑heavy Nasdaq Composite gained around 1.18%, rising alongside the day’s rebound as AI‑linked and semiconductor names snapped back from Tuesday’s rout. Volatility, however, remained elevated, a reminder that richly valued growth stocks are trading inside a policy laboratory where a single comment about minerals under Greenland’s ice sheet can move trillions in market cap.

Small‑caps, represented by the Russell 2000, also finished 2% higher, extending a year‑to‑date stretch in which smaller domestically focused companies have outpaced their mega‑cap peers. Enthusiasm for mid‑ and small‑cap names trading at a historic discount to large caps has persisted, suggesting investors are still willing to venture down the cap spectrum when macro headlines break their way.

Macroeconomic Reports

The U.S. economic calendar was relatively light, featuring housing and construction figures that painted a mixed picture. Data showed pending home sales sliding sharply in December even as construction spending and related activity in prior months held up, underscoring how quickly rate‑sensitive demand can cool once borrowing costs reset higher.

More broadly, major inflation and labor indicators for January had already been released earlier in the month, leaving Wednesday’s session to trade mostly on politics and positioning rather than fresh macro surprises. With no new shocks from growth or prices, markets used the lull to reprice risk around the evolving tariff narrative and upcoming Fed communication.

Company Highlights

Coverage and flows continued to circle around the AI and semiconductor complex that includes Nvidia (NVDA, $183.32, +2.95%), Apple (AAPL, $247.65, +.39%), Tesla (TSLA, $431.44, +2.91%), Micron (MU, $389.11, +6.61%), Intel (INTC, %54.25, +11.72%) Broadcom, Meta and Palantir, even when individual company headlines were sparse. Recent research spotlighted Nvidia and select mega‑cap tech platforms such as Apple and Meta as candidates to join or extend their stay in the two‑trillion‑dollar valuation club on the strength of AI infrastructure spending.

Eli Lilly (LLY, $1,078.52, +3.58%), TSMC, Micron, Tesla, Broadcom, Nokia (NOK, $6.44, +.47%), McDonald’s (MCD, $305.69, +.94%), Rio Tinto (RIO, $88.84, +3.69%), Oracle, Oklo, Opendoor (OPEN, $6.48, +1.41%) and others largely traded as part of broader sector moves rather than on company‑specific catalysts in Wednesday’s session. The AI and chip cohort remained central to options and momentum screens, while more defensive stalwarts such as McDonald’s and Oracle served as ballast for portfolios still wary of sudden shifts in tariff and rate expectations.

Deals, IPOs and Corporate Actions

In primary markets, the IPO spigot stayed open, with Nasdaq calendars showing fresh listings such as Santacruz Silver Mining and X3 Acquisition Corp. units in and around the January 21 window, keeping deal activity alive despite recent turbulence. Looking forward, larger aspirants including BitGo Holdings and Riku Dining Group remain in the queue for NYSE and Nasdaq debuts, signaling that bankers and issuers still see investor appetite for new paper in 2026.

Merger and buyout headlines were relatively muted, with no blockbuster deals announced to rival the day’s geopolitical drama. Corporate acquirers appear content to let valuations and borrowing costs settle around the Fed’s next move before pushing sizeable transactions into a tape that only yesterday was reminding everyone what a genuine risk‑off day feels like.

Tariffs, Greenland and Washington

The tone shift began in Davos, where President Trump announced that he had reached a “framework of a future deal” on Greenland and the Arctic region with NATO Secretary General Mark Rutte. As part of that framework, the White House said it will suspend previously announced 10% tariffs on eight European countries that had opposed U.S. ambitions over the Danish territory, defusing a trade confrontation that had rattled markets and Europe’s political class.

Reports indicated the framework contemplates U.S. participation in Greenland’s mineral rights and a proposed “Golden Dome” missile defense initiative, though details remain sparse and Denmark maintains that Greenland is not for sale. European officials, who had warned about military escalation and frozen trade negotiations in response to Washington’s earlier rhetoric, greeted the tariff reprieve cautiously, noting that NATO does not control Greenland and that sovereignty questions remain squarely in Copenhagen’s hands.

The tariff pause also eased pressure in Washington, where lawmakers had begun to weigh responses to the proposed levies amid lingering scars from the 43‑day government shutdown in 2025. While no near‑term shutdown threat dominated Wednesday’s tape, the episode reinforced that fiscal brinkmanship and trade policy can intersect quickly, especially when global investors are a captive audience in Davos.

Rates, Yield Curve and the Fed

Treasury yields drifted lower as the Greenland‑tariff de‑escalation reduced immediate safe‑haven demand without fully unwinding it. Benchmark 10‑year yields traded in the low‑4% to mid‑4% area, down from recent peaks, while shorter‑dated paper such as the 1‑year hovered around the mid‑3% range, leaving the curve modestly positive across key maturities.

Attention now turns to the Federal Open Market Committee, which is scheduled to meet January 27–28, with markets overwhelmingly expecting policymakers to hold the federal‑funds rate steady near the 3.50%–3.75% band. After three cuts in late 2025 and softer inflation readings, futures imply a gradual easing path rather than aggressive action, meaning any surprise in Chair Jerome Powell’s messaging on growth, tariffs or financial conditions could matter more than the rate decision itself.

Commodities and Crypto

Gold remained in the spotlight, hovering near record territory after a surge that took the metal above roughly 4,837.30 dollars an ounce as investors sought insurance against both policy volatility and longer‑term inflation risk. Silver pulled back to $93.12/oz.

Oil prices inched higher to $60.66/bbl, supported by a mix of supply concerns and steady demand that kept benchmark crude grinding toward recent resistance levels. Bitcoin also moved above the $90k range again.

Vista Partners Watchlist Updates

Modular Medical, Inc. (Nasdaq: MODD., $.47595), a leader in innovative insulin delivery technology targeting the $3 billion adult “almost-pumpers” diabetes market with user-friendly, affordable patch pumps, announced (Dec. 10) that it had priced an underwritten public offering (the “offering”) of 12,173,000 shares of its common stock and accompanying warrants to purchase 6,086,500 shares of its common stock. Each two shares of common stock are being offered and sold together with one accompanying warrant at a combined offering at a price of $0.77, yielding an effective price of $0.38 per share and $0.01 per warrant. The warrants will have an exercise price of $0.45 per share, are exercisable immediately upon issuance and will expire five years following the date of issuance. In connection with the offering, Modular Medical has granted the underwriter a 30-day option to purchase up to an additional 15% of common shares and/or warrants at the public offering price, less underwriting discounts and commissions. The over-allotment option may be elected with respect to, at the underwriter’s sole discretion, shares and warrants together, solely shares, solely warrants, or any combination thereof. Newbridge Securities Corporation is acting as the sole bookrunner for the offering. Assuming no exercise of the over-allotment option, the gross proceeds to the Company from the offering are expected to be approximately $4.68 million, before deducting underwriting discounts, commissions, and estimated offering expenses payable by the Company. The Company intends to use the net proceeds from the offering to fund operations and for working capital and general corporate purposes, including capital expenditures.

On Nov. 17, Modular announced Institutional Review Board (“IRB”) approval to conduct an in-house study of its next-generation Pivot™ insulin delivery system using insulin on people with diabetes (the “Study”). Pursuant to U.S. Food and Drug Administration (“FDA”) regulations, an IRB is a group that has been formally designated to review and monitor biomedical research involving human subjects. The Study will simulate real-world conditions by delivering insulin to adult participants to gather critical data on device function and usability and obtain user feedback. Modular Medical’s Pivot tubeless patch pump aims to enhance accessibility for underserved patients with diabetes and drive market penetration and expansion.

On Nov. 14, Modular Medical announced the 510(k) premarket submission of its next generation Pivot™ tubeless patch pump to the U.S. Food and Drug Administration (the “FDA”). The Company expects to commence the commercial launch of its Pivot pump in Q1 2026. On Nov. 3, Modular Medical the successful validation of its Pivot controller line, a critical milestone in preparing for the commercial launch of its Pivot patch pump targeted for Q1 2026. The Pivot controller line validation further demonstrates manufacturing readiness for high-volume production, positioning Modular Medical to meet the growing demand in the diabetes treatment market for advanced technology.

Eupraxia Pharmaceuticals Inc. (NASDAQ: EPRX, $9.03, +.11%), a clinical-stage biotechnology company leveraging its proprietary Diffusphere™ technology to optimize local, controlled drug delivery for diseases with significant unmet need, announced (Nov. 13) the second set of 52-week follow up data from its ongoing Phase 1b/2a RESOLVE trial evaluating a single administration EP-104GI for the treatment of eosinophilic esophagitis (“EoE”). James A. Helliwell, Chief Executive Officer of Eupraxia stated,“These data further highlight the strong durability and tolerability profile of EP-104GI, reinforcing its potential to become a convenient, once-a-year treatment that fits seamlessly into routine disease management by aligning with annual patient endoscopies. The Cohorts 5 & 6 patients – the only groups to have reached 52 weeks in the trial – are demonstrating levels of symptom relief that is durable and clinically meaningful – we are very encouraged by this outcome. We’re also pleased that our previously announced 52-week data were presented as a late-breaking presentation at the American College of Gastroenterology Annual Scientific Meeting (ACG). These new results build on that momentum. Given that current EoE therapies often struggle with long-term adherence, we believe a durable, once-yearly treatment could meaningfully improve patient outcomes and establish EP-104GI as a preferred option for both physicians and their patients.”

GeoVax Labs, Inc. (Nasdaq: GOVX, $2.98, +6.81%), a clinical-stage biotechnology company developing multi-antigen vaccines and immunotherapies for infectious diseases and cancer.

GeoVax is heading into the 44th Annual J.P. Morgan Healthcare Conference week (“JPM2026”) in San Francisco, CA Jan. 12-15 with the kind of narrative biotech investors typically like to hear: a differentiated platform, large funded trials lining up, and multiple shots on goal in both infectious disease and oncology. The company is leaning into its MVA platform as a potential franchise engine rather than a one‑product science experiment. Specifically, investors can meet David Dodd, Chairman & CEO of GeoVax, during his presentation at the Hilton Union Square, 333 O’Farrell Street, Yosemite A (Ballroom Level), San Francisco, CA on January 13, 2026, 2:30 pm PST.

GeoVax announced (Dec. 19) that it has entered into definitive securities purchase agreements with several institutional and individual investors for the purchase and sale of approximately 13.2 million units, each comprised of one share of the Company’s common stock and warrants, as described below, to purchase shares of the Company’s common stock, at a price of $0.245 per unit in a public offering. The Company will issue warrants to purchase up to approximately 26.5 million shares of common stock. The warrants will have an exercise price of $0.245 per share, will be exercisable immediately following the date of issuance and will have a term of five years following the date of issuance. Roth Capital Partners is acting as the exclusive placement agent for the offering. The gross proceeds to the Company from this offering are expected to be approximately $3.2 million, before deducting the placement agent’s fees and other offering expenses payable by the Company. The Company intends to use the net proceeds from this offering for working capital and general corporate purposes. The closing of the offering is expected to occur on or about December 22, 2025, subject to the satisfaction of customary closing conditions.

GeoVax announced (Dec. 18) the publication of a peer-reviewed article in Frontiers in Immunology titled: “Multi-antigen MVA-vectored SARS-CoV-2 vaccine, GEO-CM04S1, induces cross-protective immune responses to ancestral and Omicron variants.” The study provides definitive preclinical evidence that GeoVax’s multi-antigen COVID-19 vaccine candidate, GEO-CM04S1, delivers full cross-variant protection, driven predominantly by robust T-cell responses, even in the absence of neutralizing antibodies. The findings reinforce the design philosophy behind GeoVax’s MVA-based, multi-antigen platform and provide mechanistic insight that is increasingly relevant for immunocompromised individuals, who often fail to respond optimally to the first-generation COVID-19 vaccines.

GeoVax announced (Dec. 17) the successful completion of fill-finish for the initial clinical batch of GEO-MVA, its next-generation Mpox/smallpox vaccine. The product has now entered final release evaluation, the concluding quality-control and compliance process required before shipment for clinical use, positioning the Company for Phase 3 immunobridging trial start-up activities in Q1 2026. Fill-finish – the sterile, cGMP-regulated process of filling, sealing, and packaging vaccine vials – marks the last manufacturing step before a vaccine may enter clinical study supply channels. With fill-finish complete and GEO-MVA now undergoing final release evaluation, GeoVax has moved into the final pre-clinical-deployment phase of its EMA-aligned clinical program. In June 2025, the European Medicines Agency (EMA) Scientific Advice confirmed that a single Phase 3 immunobridging study demonstrating immune comparability to the approved MVA vaccine, Imvanex(R), would be sufficient to evaluate GEO-MVA’s efficacy. This provides a clear, accelerated regulatory path to licensure. This milestone coincides with increasing Mpox activity globally – including expanding Clade I outbreaks in Africa and emerging cases in the United States – exposing vulnerabilities associated with global dependence on a sole foreign MVA vaccine supplier. GEO-MVA is designed to expand supply, diversify sources, and strengthen biodefense infrastructure.

Volato Group, Inc. (NYSE American: SOAR, $.49) and M2i Global, Inc. (MTWO, $.05, +3.95%), a company specializing in the development and execution of a complete global value supply chain for critical minerals, reaffirmed, on Tuesday, Jan. 20, their expectation to complete their targeted first-quarter 2026 closing timeline for the previously announced business combination, citing steady advancement through the SEC review process alongside continued progress in operational planning and integration readiness. Subject to the effectiveness of the registration statement on Form S-4, stockholder approvals, and other customary closing conditions, the companies continue to expect the merger to close in the first quarter of 2026. To align the transaction timeline with the current stage of the SEC review process, the companies have mutually agreed to extend the end date of the merger agreement through March 31, 2026. This extension reflects disciplined execution and provides additional runway to complete the remaining regulatory steps in an orderly manner, while maintaining transaction commitment and protecting stockholder interests. Amendment No. 1 to the Form S-4 was filed on Monday, January 12, 2026, to respond to SEC comments and advance the registration statement through the review process. The review timeline was affected in part by a temporary slowdown in SEC operations following the recent federal government shutdown. With the amendment now on file, the companies are focused on completing the remaining steps of the SEC review process.

On Jan. 9, M2i Global and Volato Group announced that they have entered into a strategic collaboration agreement with Australian company Titanium X to advance critical mineral development in the US. This partnership represents a significant move towards enhancing domestic refining capacity and strengthening the critical materials supply chain that underpins US industry and national security. Titanium X and M2i Global will work together on the financing, development and commercialisation of the former’s critical mineral assets. M2i Global will apply its global experience in delivering mineral projects to support these initiatives. The companies are also in talks to conclude an exclusive titanium concentrate supply agreement.

On Jan. 7, M2i Global, Inc. along with Volato Group, Inc. (“Volato”) (NYSE American: SOAR), a technology-driven company, announced a strategic collaboration agreement with Titanium X, marking a major step forward in advancing domestic refining capabilities and securing the critical materials supply chain essential to U.S. industry and national security.

Volato Group, Inc. today (Dec. 29) announced the appointment of Alan D. Gaines to its Board of Directors, effective immediately. Mr. Gaines will also serve as Chairman of the Audit Committee.

On Dec. 23, Volato Group, Inc. announced preliminary financial guidance for the fourth quarter and full year ending December 31, 2025, reflecting continued execution against its strategic and balance sheet objectives. For the fourth quarter of 2025, Volato expects to report revenue between $27 million and $28 million. For the full year 2025, the Company anticipates total revenue between $78 million and $79 million, with net income of $6 million to $8 million. These results reflect a year of meaningful progression aligning operational performance with Volato’s long-term growth initiatives and advancing its pending merger with M2i Global, Inc. (OTC: MTWO). During 2025, Volato also made substantial progress strengthening its balance sheet. As of September 30, 2025, the Company reduced total liabilities to $9.5 million, satisfying the debt reduction condition required under its pending merger agreement with M2i Global, Inc. (OTC: MTWO). Volato expects continued improvement in its capital structure as it advances toward a targeted first-quarter 2026 closing of the transaction. “Our 2025 results reflect a year of transformation and disciplined balance sheet execution,” said Mark Heinen, Chief Financial Officer of Volato. “We made significant progress reducing liabilities while sharpening our focus on scalable, technology-driven businesses that are designed to complement and strengthen the M2i Global platform over the long term.”

Serina Therapeutics (NYSE American: SER, $2.85), Alabama-based biotech is betting its proprietary POZ platform and reimagined approach to apomorphine delivery may redefine the treatment paradigm for patients who have exhausted standard oral therapies. On Dec. 11, Serina announced the appointment of Joshua Thomas, Ph.D., as Vice President and Head of Chemistry. He will oversee internal and external chemistry efforts to optimize POZ-based candidates, supporting efficient translation from discovery through development.

On Dec. 10, Serina announced that it has submitted a complete response to the U.S. Food and Drug Administration’s (“FDA”) clinical hold letter for SER-252, the Company’s lead program for advanced Parkinson’s disease. As previously disclosed, the FDA placed the Company’s Investigational New Drug (“IND”) application for SER-252 on clinical hold pending additional information related to a commonly used formulation excipient. On November 25, 2025, the FDA issued a formal full clinical hold letter specifying the information required to permit initiation of the planned Phase 1b registrational study, SER-252-1b. The issues identified by the FDA do not relate to the apomorphine active drug substance, its mechanism of action, the use of the enFuse device (Enable Injections) or the broader 505(b)(2) NDA development pathway previously discussed with the Agency.

The InterGroup Corporation (NASDAQ: INTG, $29.36) announced (Jan. 6) that on December 29, 2025, it completed the sale of a non-core 12-unit apartment complex in Los Angeles County for a gross sales price of approximately $4,850,000. InterGroup expects to report a GAAP net gain on sale of approximately $3,509,000, which will be reflected in the Company’s Form 10‑Q for the quarter ended December 31, 2025. The transaction is expected to result in federal and state income tax liability, the amount of which will be determined based on the Company’s final tax position and applicable tax rules.

DoubleVerify Holdings Inc. (DV) closed at $10.52. DoubleVerify, which built its franchise on media verification and ad performance analytics, is now the first badged TikTok Marketing Partner focused specifically on attention measurement, tapping impression-level signals from the platform. Brands gain a granular view of how exposure and user interaction come together across TikTok formats, ad sets, creatives, and objectives, effectively treating every swipe as a tiny A/B test.

flyExclusive, Inc. (NYSE American: FLYX, $3.28, +1.55%), one of the nation’s largest private jet operators and a certified Part 145 Repair Station, today announced it has signed an authorized dealership agreement with Starlink, becoming a certified dealer and installer for Starlink’s high-speed, low-latency aviation connectivity system.

The Sources

1. Reuters – “Wall Street jumps on Greenland framework deal”
   https://www.reuters.com/business/us-stock-futures-steady-after-wall-street-rout-eyes-trump-davos-2026-01-21/[reuters]​
2. CNBC – “Trump says he reached Greenland deal ‘framework’ with NATO, will not impose tariffs”
   https://www.cnbc.com/2026/01/21/trump-tariffs-nato-greenland-davos.html[cnbc]​
3. Yahoo Finance – “Stock market today: Dow surges 550 points, S&P 500, Nasdaq jump as Trump backs off Greenland tariff threats”
   https://finance.yahoo.com/news/live/stock-market-today-dow-surges-550-points-sp-500-nasdaq-jump-as-trump-backs-off-greenland-tariffs-[finance.yahoo]​
4. ABC News – “Trump stands down on NATO tariff threat, citing ‘framework’ for a Greenland deal”
   https://abcnews.go.com/Politics/trump-stands-nato-tariff-threat-citing-framework-deal/story?id=129430043[abcnews.go]​
5. The Hill – “Trump agrees to ‘framework’ deal on Greenland, retreats on European tariffs”
   https://thehill.com/homenews/administration/5699533-trump-greenland-nato-tariffs-deal/[thehill]​
6. Al Jazeera – “Trump nixes European tariff threats over Greenland after NATO chief talks”
   https://www.aljazeera.com/news/2026/1/21/trump-nixes-european-tariff-threats-over-greenland-after-nato-chief-talks[aljazeera]​
7. Reuters (analysis) – “Investor reaction as U.S. President Trump withdraws tariff threat, says Greenland deal framework reached”
   https://www.reuters.com/business/finance/view-investor-reaction-us-president-trump-withdraws-tariff-threat-says-greenland-2026-01-21/[reuters]​
8. Yahoo Finance – “Wall Street rebounds after Trump announces the framework for a deal on Greenland, calls off tariffs”
   https://ca.finance.yahoo.com/news/us-futures-edge-higher-gold-045640262.html[ca.finance.yahoo]​
9. New York Post (via Reuters) – “Dow surges 700 points amid Trump–Greenland framework, tariff threat called off”
   https://nypost.com/2026/01/21/business/dow-surges-700-points-amid-trump-greenland-framework-tariff-threat-called-off/[nypost]​
10. Wall Street Journal – “Stock Market Today: Dow Gains 200 Points After Trump Speech” (live coverage)
    https://www.wsj.com/livecoverage/stock-market-today-fed-lisa-cook-trump-nvidia-01-21-2026[wsj]​